CoChat

Oral propionyl‐ l ‐carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease

Cavallini, G., Biagiotti, G., Koverech, A., Vitali, G. · 2002 · BJU International
Cited by 98

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Objective To ascertain whether oral propionyl‐ l ‐carnitine combined with intraplaque verapamil is a useful therapy for advanced or resistant Peyronie's disease. Patients and methods The combined drugs were assessed in two studies. In the first, 60 patients with advanced Peyronie's disease, diagnosed using accepted definitions, were randomized in two subgroups treated with verapamil intraplaque infiltration (10 mg weekly for 10 weeks) plus a 3‐month administration of propionyl‐ l ‐carnitine (2 g/day), or verapamil infiltration plus oral tamoxifen (40 mg/day) for 3 months. In the second study, 15 patients with resistant Peyronie's disease (progression despite previous therapy) received verapamil plus propionyl‐ l ‐carnitine. The differences between subgroups or between the variables before and after therapy were compared using analysis of variance or the chi‐squared test. Results In the first study, the reduction in pain was the same in both subgroups. Propionyl‐ l ‐carnitine plus verapamil significantly reduced penile curvature, plaque size, cavernosal artery end‐diastolic velocity, the need for surgery and disease progression, and increased the International Index of Erectile Function score and resistivity index of the cavernosal arteries. Tamoxifen plus verapamil had none of these effects. No drug combination affected the peak systolic velocity. Patients receiving verapamil had no side‐effects but those taking tamoxifen did. In the second study propionyl‐ l ‐carnitine and verapamil modified the disease patterns as in the first and no patient had side‐effects. Conclusion The combination of propionyl‐ l ‐carnitine and verapamil can be considered the therapy of choice for advanced and resistant Peyronie's disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1464-410x.2002.02738.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 98

Metadata

Authors
Cavallini, G., Biagiotti, G., Koverech, A., & Vitali, G.
Venue
BJU International
Publisher
Wiley
Published
2002-05-12
Volume
89
Issue
9
Pages
895-900
ISSN
  • 1464-4096 (ISSN-L)
  • 1464-410X
OpenAlex
W1526108749
Cited by
98
References
1
FWCI
3.03
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Oral propionyl‐ l ‐carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease. https://app.cochat.ai/papers/10.1046/j.1464-410x.2002.02738.x
The paper
Cavallini, G., Biagiotti, G., Koverech, A., & Vitali, G. (2002). Oral propionyl‐ l ‐carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease. BJU International. https://doi.org/10.1046/j.1464-410x.2002.02738.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.